The article examines the objective, findings, and clinical context described in Refining Animal Research: Using ‘Omics Technologies to Connect NAMs with More Informative Regulatory Studies.
Approach:
Tiered assessment: In silico and in vitro evidence can guide targeted in vivo studies when earlier evidence is insufficient, focusing on toxicological modes of action relevant to the substance.
Information-rich studies: Alongside conventional toxicology endpoints, studies may include toxicokinetics, metabolomics, transcriptomics in selected target organs, and other omics technologies.
Regulatory framework: The article relates these studies to Technical Guideline Plus (TG+) studies, which follow an OECD Test Guideline while adding mechanistic data.
Key Findings:
NAMs have advanced substantially, but validation, regulatory acceptance, and integration of expanding assay data remain challenges.
The context states that current NAMs alone are not yet sufficient to demonstrate absence of risk or hazard, particularly for effects involving multiple organs.
Mechanistic data from smart in vivo or TG+ studies may support hazard characterization, human-relevance evaluations, read-across, and potentially study-waiving strategies.
Generating more information from each required animal study is presented as a way to connect refinement with reduction, termed “Reduction through Refinement.”
Interpretation:
The article presents omics-enhanced in vivo studies as a bridge between conventional regulatory studies and NAM-based approaches, while retaining regulatory requirements and adding mechanistic information.
Limitations:
The provided context ends mid-sentence, so any subsequent discussion or qualifications are unavailable.
The context does not provide study-level results or quantitative evidence for the proposed benefits.
